Finance
Finance
āĻŽāĻžāĻ°ā§āϕ⧇āϟ
āĻšā§‹āĻŽSBHMY â€ĸ OTCMKTS
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
⧍ā§Ļ.ā§§ā§Ŧ$
⧧⧍ āϏ⧇āĻĒ, ⧧⧍:⧍ā§Ļ:ā§¨ā§Š AM GMT -ā§Ē · USD · OTCMKTS · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻ¸ā§āϟāĻ•āĻŽāĻžāĻ°ā§āĻ•āĻŋāύ āϝ⧁āĻ•ā§āϤāϰāĻžāĻˇā§āĻŸā§āϰ-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
⧍ā§Ļ.ā§§ā§Ŧ$
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
ā§­.ā§§ā§Ģ$ - ⧍ā§Ļ.ā§§ā§Ŧ$
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
ā§§ā§Ŧā§§.⧝⧧āϕ⧋ HKD
āĻ—āĻĄāĻŧ āĻ­āϞāĻŋāωāĻŽ
ā§Ēā§Š.ā§Ļā§Ļ
P/E āĻ…āύ⧁āĻĒāĻžāϤ
-
āϞāĻ­ā§āϝāĻžāĻ‚āĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻ–āĻŦāϰ⧇ āĻ°ā§Ÿā§‡āϛ⧇
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(CNY)āϜ⧁āύ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
ā§Žā§­ā§Ž.ā§­ā§Ē āϕ⧋⧧ā§Ļ.ā§­ā§§%
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
ā§Ģā§Ģā§Ē.⧍ā§Ŧ āϕ⧋⧧ā§Ģ.⧝ā§Ŧ%
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§§ā§Ŧ⧝.ā§Ēā§ŠÂ āϕ⧋⧧⧍.ā§Šā§§%
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
⧧⧝.ā§¨ā§Žā§§.ā§Ē⧍%
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
——
EBITDA
⧧⧝⧭.ā§­ā§§Â āϕ⧋ā§Ļ.ā§Ļā§Ž%
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
ā§§ā§Ŧ.ā§Ēā§Ģ%—
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(CNY)āϜ⧁āύ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
⧧⧝.ā§Žā§¨āĻļāĻ¤Â āϕ⧋ā§Ģā§Ļ.ā§Ēā§§%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§­ā§Ē.ā§Žā§¯āĻļāĻ¤Â āϕ⧋⧧⧍.ā§¨ā§Ž%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
⧍⧝.⧧⧍āĻļāĻ¤Â āĻ•ā§‹ā§§ā§Ž.ā§Ēā§Ģ%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
ā§Ēā§Ģ.ā§­ā§ŽāĻļāĻ¤Â āĻ•ā§‹â€”
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§§ā§Ž.ā§Ļā§ĻāĻļāĻ¤Â āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
ā§§ā§Ļ.⧝ā§Ļ—
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§Ģ.ā§Ŧ⧝%—
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§­.ā§Šā§Ž%—
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(CNY)āϜ⧁āύ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
ā§§ā§Ŧ⧝.ā§Ēā§ŠÂ āϕ⧋⧧⧍.ā§Šā§§%
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
——
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
——
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
——
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
——
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
——
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
āϏāĻŋāχāĻ“
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
⧍ā§Ļā§Ļā§Ļ
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
ā§¨ā§Š,ā§Ļā§Ģā§Ŧ
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϞ⧋āĻ•āϜāύ āĻāϗ⧁āϞāĻŋāĻ“ āĻ–ā§‹āρāĻœā§‡āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁